Valuation: Myriad Genetics, Inc.

Market Cap 434M 386M 360M 328M 619M 41.75B 625M 4.36B 1.69B 21.34B 1.63B 1.59B 68.49B P/E 2026 *
-2.9x
P/E 2027 * -3.47x
Enterprise Value 385M 342M 319M 291M 549M 37.04B 554M 3.87B 1.5B 18.93B 1.45B 1.42B 60.76B EV / Sales 2026 *
0.5x
EV / Sales 2027 * 0.44x
Free-Float
95.94%
Yield 2026 *
-
Yield 2027 * -
1 day+11.82%
1 week+8.87%
Current month+5.34%
1 month+40.56%
3 months-24.21%
6 months-4.42%
Current year-26.18%
1 week 4.06
Extreme 4.055
4.58
1 month 3.06
Extreme 3.06
4.58
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
33.09
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Tax

Chief Financial Officer

-2,555 0.0027%
9/16/26 Free

Executive/Senior Manager

257,731 0.2695%
9/16/26 Other

Executive/Senior Manager

93,493 0.0977%
Change 5-day change 1-year change 3-year change Capi.($)
+11.82%+8.87%-39.95%-70.73% 434M
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average +0.96%+0.12%-13.38%+4.13% 69.06B
Weighted average by Cap. +0.03%-1.29%-16.38%+10.08%

Financials

2026 *2027 *
Net sales 778M 691M 645M 588M 1.11B 74.78B 1.12B 7.81B 3.03B 38.23B 2.92B 2.86B 123B 821M 729M 681M 621M 1.17B 78.92B 1.18B 8.24B 3.19B 40.34B 3.08B 3.02B 129B
Net income -140M -124M -116M -106M -199M -13.42B -201M -1.4B -543M -6.86B -524M -513M -22.02B -106M -94.38M -88.09M -80.29M -151M -10.21B -153M -1.07B -413M -5.22B -399M -390M -16.75B
Net Debt -49M -43.53M -40.63M -37.03M -69.85M -4.71B -70.5M -492M -191M -2.41B -184M -180M -7.73B -74.14M -65.87M -61.48M -56.04M -106M -7.13B -107M -744M -288M -3.64B -278M -272M -11.69B
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-10-02 US$4.540 +11.82% 2,281,249
26-10-01 US$4.060 -5.80% 1,657,900
26-09-30 US$4.310 +1.89% 1,504,783
26-09-29 US$4.230 -0.24% 1,599,334
26-09-28 US$4.240 +1.68% 1,181,318
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
4.540USD
Average target price
3.912USD
Spread / Average Target
-13.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock